Processing

Please wait...

Settings

Settings

Goto Application

1. WO2020197400 - ENGINEERED IGA ANTIBODIES AND METHODS OF USE

Publication Number WO/2020/197400
Publication Date 01.10.2020
International Application No. PCT/NL2020/050217
International Filing Date 27.03.2020
IPC
C07K 16/00 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
C07K 16/28 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
C07K 16/30 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
30from tumour cells
C07K 16/32 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
32against translation products from oncogenes
CPC
C07K 16/00
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
C07K 16/2803
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
2803against the immunoglobulin superfamily
C07K 16/2818
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
2803against the immunoglobulin superfamily
2818against CD28 or CD152
C07K 16/2887
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
2887against CD20
C07K 16/3084
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
30from tumour cells
3076against structure-related tumour-associated moieties
3084against tumour-associated gangliosides
C07K 16/32
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
32against translation products of oncogenes
Applicants
  • UMC UTRECHT HOLDING B.V. [NL]/[NL]
Inventors
  • LEUSEN, Jeannette Henrica Wilhelmina
  • EVERS, Johannes Gerardus Maria
  • VAN TETERING, Geert Jan
Agents
  • WITMANS, H.A.
Priority Data
62/824,86427.03.2019US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) ENGINEERED IGA ANTIBODIES AND METHODS OF USE
(FR) ANTICORPS IGA MODIFIÉS ET PROCÉDÉS D'UTILISATION
Abstract
(EN)
Provided herein are engineered antibodies that comprise a modified IgA heavy chain constant region, pharmaceutical compositions, and methods of use. The engineered antibodies described herein comprise one or more amino acid substitution or deletion in a constant region of an IgA domain. Further provided herein are methods of treating disorders, including cancer, by administering an engineered IgA antibody described herein.
(FR)
La présente invention concerne des anticorps modifiés qui comprennent une région constante de chaîne lourde d'IgA modifiée, des compositions pharmaceutiques et des procédés d'utilisation. Les anticorps modifiés selon l'invention comprennent une ou plusieurs substitutions ou délétion d'acides aminés dans une région constante d'un domaine IgA. L'invention concerne en outre des procédés de traitement de troubles, y compris le cancer, par l'administration d'un anticorps IgA modifié décrit ici.
Latest bibliographic data on file with the International Bureau